<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848106</url>
  </required_header>
  <id_info>
    <org_study_id>REG1-CLIN310</org_study_id>
    <secondary_id>2013-001384-23</secondary_id>
    <nct_id>NCT01848106</nct_id>
  </id_info>
  <brief_title>A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI</brief_title>
  <acronym>Regulate</acronym>
  <official_title>A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regado Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian VIGOUR Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regado Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the efficacy of REG1 compared to bivalirudin in&#xD;
      preventing periprocedural ischemic complications and major bleeding in patients undergoing&#xD;
      PCI as a treatment for CAD. Bivalirudin has been studied in patients undergoing PCI in both&#xD;
      ACS (NSTEMI and unstable angina [UA]) and elective PCI. In comparison to UFH, bivalirudin has&#xD;
      shown similar rates of ischemic events while demonstrating a significant reduction in&#xD;
      bleeding and an improved net clinical benefit.&#xD;
&#xD;
      Evidence from previous studies indicates that pegnivacogin represents an extremely potent,&#xD;
      chemically unique anticoagulant that can be reversed by anivamersen across multiple&#xD;
      populations (refer to Section 1.2.2). The question that still remains is whether Factor IX&#xD;
      (FIX) inhibition by pegnivacogin can result in fewer ischemic events than a previously&#xD;
      studied agent while active control with anivamersen can preserve the benefit of reduced&#xD;
      bleeding. The purpose of this study is to evaluate REG1 in an adequately powered definitive&#xD;
      study with an open-label, multi-center, active-controlled, randomized design to answer that&#xD;
      question.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Clinical Hold&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemic composite</measure>
    <time_frame>Day 3</time_frame>
    <description>The primary efficacy endpoint is the composite of death, nonfatal myocardial infarction, nonfatal stroke and urgent TLR through Day 3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3232</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bivalirudin bolus and infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reg 1 (pegnivacogin/anivamersen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus pegnivacogin plus anivamersen active control agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegnivacogin/anivamersen</intervention_name>
    <arm_group_label>Reg 1 (pegnivacogin/anivamersen)</arm_group_label>
    <other_name>Reg 1 Anticoagulation System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Angiox, Angiomax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The study population will consist of patients with CAD undergoing PCI. Three key&#xD;
             subgroups will be included&#xD;
&#xD;
          2. Willing and able to sign an Institutional Review Board/Ethics Committee (IRB/EC)&#xD;
             approved informed consent prior to any study-related activities;&#xD;
&#xD;
          3. Male or female age 18 or greater;&#xD;
&#xD;
          4. If female of childbearing potential, must have a negative urine or serum pregnancy&#xD;
             test or be post-menopausal for at least 1 year prior to randomization. Females of&#xD;
             childbearing potential must be practicing adequate birth control to be eligible. It is&#xD;
             the Investigator's responsibility for determining whether the patient has adequate&#xD;
             birth control for study participation;&#xD;
&#xD;
          5. Subject is able and willing to comply with the protocol and all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute ST-segment elevation myocardial infarction within 48 hours of randomization;&#xD;
&#xD;
          2. Evidence of current clinical instability&#xD;
&#xD;
          3. Evidence of a contraindication to anticoagulation or increased risk of bleeding&#xD;
&#xD;
          4. Use of any investigational drug or device within 30 days of randomization or the&#xD;
             planned use of an investigational drug or device through EOS (Day 30 follow-up);&#xD;
&#xD;
          5. Use of the select antithrombotic agents&#xD;
&#xD;
          6. Baseline hemoglobin (Hgb) &lt;9 g/dL or equivalent;&#xD;
&#xD;
          7. Baseline estimated glomerular filtration rate (GFR) ≤ 10 mL/min/1.73m² or currently&#xD;
             undergoing renal replacement therapy (hemodialysis or peritoneal dialysis);&#xD;
&#xD;
          8. Baseline platelet count &lt;100,000/mm3;&#xD;
&#xD;
          9. Known allergy or intolerance to aspirin, to all available ADP/P2Y12 inhibitors&#xD;
             (clopidogrel, prasugrel, ticagrelor), or to bivalirudin or REG1 (or any of their&#xD;
             respective components);&#xD;
&#xD;
         10. The following planned procedures: a. Planned staged PCI procedure within 3 days after&#xD;
             randomization; b. Planned CABG or valve surgery within 30 days after randomization;&#xD;
&#xD;
         11. Any other medical or psychiatric condition that in the Investigator's judgment&#xD;
             precludes participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L Zelenkofske, DO, FACC</last_name>
    <role>Study Director</role>
    <affiliation>Regado Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Michael Lincoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John H Alexander, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Regado</keyword>
  <keyword>Reg 1</keyword>
  <keyword>bivalirudin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

